Beyond Air Inc (OQ:XAIR)
Business Focus: Medical Equipment, Supplies & Distribution
| Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 900 STEWART AVENUE, SUITE 301 GARDEN CITY NY 11530 |
| Tel: | N/A |
| Website: | https://www.beyondair.net |
| IR: | See website |
| Key People | ||
| Steven A. Lisi Chairman of the Board, Chief Executive Officer | Amir Avniel President, Director, Chief Business Officer | Douglas Q. Larson Chief Financial Officer |
| Michael Gaul Chief Operating Officer | Jeff Myers Chief Medical Officer | |
| Business Overview |
| Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (NO) generators and delivery systems (the LungFit platform) capable of generating NO from ambient air. The Company's LungFit platform can be used to treat patients on ventilators that require NO, as well as patients with chronic or acute severe lung infections through delivery through a breathing mask or similar apparatus. The Company's areas of focus with LungFit are persistent pulmonary hypertension of the newborn (PPHN), viral community-acquired pneumonia (VCAP), including COVID-19, bronchiolitis (BRO), nontuberculous mycobacteria (NTM) lung infection and various severe lung infections with underlying chronic obstructive pulmonary disease (COPD). Its LungFit PH is an ionizer technology that generates on-demand NO from ambient air and, regardless of dose or flow, delivers it to a ventilator circuit. The LungFit can generate up to 400 parts per million (ppm) of NO. |
| Financial Overview |
| For the nine months ended 31 December 2023, Beyond Air Inc revenues increased from $0K to $689K. Net loss applicable to common stockholders increased 31% to $46.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 55% to $14.7M (expense), Stock-based Compensation in SGA increase of 25% to $15M (expense). |
| Employees: | 98 as of Mar 31, 2023 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $42.00M as of Dec 31, 2023 |
| Annual revenue (TTM): | $0.69M as of Dec 31, 2023 |
| EBITDA (TTM): | -$62.78M as of Dec 31, 2023 |
| Net annual income (TTM): | -$66.70M as of Dec 31, 2023 |
| Free cash flow (TTM): | -$59.57M as of Dec 31, 2023 |
| Net Debt Last Fiscal Year: | N/A |
| Shares outstanding: | 45,898,321 as of Mar 20, 2024 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.